Travere Therapeutics (TVTX) Cash & Equivalents (2016 - 2025)
Historic Cash & Equivalents for Travere Therapeutics (TVTX) over the last 16 years, with Q3 2025 value amounting to $110.9 million.
- Travere Therapeutics' Cash & Equivalents rose 20467.74% to $110.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $110.9 million, marking a year-over-year increase of 20467.74%. This contributed to the annual value of $58.5 million for FY2024, which is 61.71% up from last year.
- According to the latest figures from Q3 2025, Travere Therapeutics' Cash & Equivalents is $110.9 million, which was up 20467.74% from $75.2 million recorded in Q2 2025.
- Travere Therapeutics' Cash & Equivalents' 5-year high stood at $256.6 million during Q1 2022, with a 5-year trough of $32.3 million in Q2 2024.
- For the 5-year period, Travere Therapeutics' Cash & Equivalents averaged around $107.9 million, with its median value being $83.3 million (2021).
- As far as peak fluctuations go, Travere Therapeutics' Cash & Equivalents crashed by 7475.87% in 2024, and later skyrocketed by 20467.74% in 2025.
- Quarter analysis of 5 years shows Travere Therapeutics' Cash & Equivalents stood at $165.8 million in 2021, then plummeted by 62.78% to $61.7 million in 2022, then fell by 5.69% to $58.2 million in 2023, then grew by 0.62% to $58.5 million in 2024, then surged by 89.51% to $110.9 million in 2025.
- Its Cash & Equivalents stands at $110.9 million for Q3 2025, versus $75.2 million for Q2 2025 and $61.9 million for Q1 2025.